{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 49 of 92', 'CR845-CLIN3103', 'i.', 'To be completed in the dialysis unit at any time prior to or during dialysis, but must be done prior to dosing. Preferably at the end of the specified week, which corresponds to', 'the beginning of the following calendar week (ie, end of Week 4 is the Monday/Tuesday of Week 5).', 'j.', 'Biomarker samples must be collected prior to the start of dialysis.', 'k.', 'Adverse events and concomitant medications will be recorded starting on Day 1 of the Open-label Extension Phase.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 50 of 92', 'CR845-CLIN3103', '6.5.3', 'Efficacy Assessments', 'The effect of CR845 on itch will be measured by means of the following PRO measures:', 'Worst Itching Intensity NRS score', 'Skindex-10 Scale', '5-D Itch Scale', 'Patient Global Impression of Change', 'Patients will be trained on completion of the Worst Itching Intensity NRS scale prior to', 'the first visit of the Run-in Period, and will be trained on the other itch-related PRO', 'measures at any time prior to Day 1 of the Double-blind Treatment Period. All', 'questionnaires must be completed in strict adherence to the Training Manual for Patient', 'Reported Assessments.', '6.5.3.1', 'Worst Itching Intensity Numerical Rating Scale', 'Intensity of itch will be measured using an NRS scale (Appendix 2, Section 14.2) on a', 'worksheet on which patients will be asked to indicate the intensity of the worst itching', 'they experienced over the past 24 hours by marking one of 11 numbers, from 0 to 10, that', 'best describes it, where \"0\" is labeled with the anchor phrase \"no itching\" and \"10\" is', 'labeled \"worst itching imaginable.\" Patients will be provided with these worksheets to', 'record their 24-hour worst itching assessment scores, both at the clinic on dialysis days', 'and at home on nondialysis days.', 'The Worst Itching Intensity NRS has been widely utilized for evaluation of chronic itch,', 'including uremic pruritus [Kumagai 2010; Pisoni 2006; Mathur 2010; St\u00e4nder 2013].', '6.5.3.2', 'Skindex-10 Scale', 'Developed specifically for uremic pruritus, the Skindex-10 Scale (Appendix 3,', 'Section 14.3) is an instrument for measurement of quality-of-life that correlates with itch', 'intensity [Mathur 2010]. Patients are asked to mark 1 of 7 boxes numbered from 0', '(labeled with the anchor phrase \"never bothered\") to 6 (labeled as \"always bothered\") for', 'each of the 10 questions describing how often they have been bothered by their itch and', 'its impact over the past week. The total score is the sum of the numeric value of each', 'answered question. The total score is subdivided into 3 domain scores, which are sums', 'of the scores of the following questions: disease domain (questions 1 to 3),', 'mood/emotional distress domain (questions 4 to 6), and social functioning domain', '(questions 7 to 10).', '6.5.3.3', '5-D Itch Scale', 'The 5-D Itch Scale was developed as a brief, multidimensional questionnaire designed to', 'be useful as an outcome measure in clinical studies. The 5 dimensions of itch assessed', 'are degree, duration, direction, disability, and distribution (Appendix 4, Section 14.4).', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 51 of 92', 'CR845-CLIN3103', 'Patients are asked to mark boxes that best describe the impact of their itch over the past', '2 weeks. The scale has been validated in patients with chronic pruritus, including', 'hemodialysis patients and has been shown to be sensitive to changes in pruritus over time', '[Elman 2010].', '6.5.3.4', 'Patient Global Impression of Change', 'The Patient Global Impression of Change is a global PRO measure that assesses the', 'change in itch (no change, improvement or worsening) overall relative to the start of the', 'study [Dworkin 2005]. The scale has only 1 item, and the patient is asked to mark the', 'category that best describes the change in itch ranging from \"Very Much Improved\" to', '\"Very Much Worse\" (Appendix 5, Section 14.5).', '6.5.4', 'Safety Assessments', 'During both the Double-blind and Open-label Extension Phases, the safety assessments', 'for each patient are the following:', 'Severity, seriousness, and relationship of adverse events to study drug', 'Structured Safety Evaluation by site staff (Double-blind Phase only)', 'Physical examination', 'Vital signs', '12-lead ECGs', 'Clinical laboratory tests', '6.5.4.1', 'Adverse Events', 'Definition of Adverse Events', 'An adverse event is any untoward medical occurrence in a patient or clinical', 'investigational patient administered a medicinal product and which does not necessarily', 'have to have a causal relationship with this treatment. An adverse event can therefore be', 'any unfavorable and unintended sign (including an abnormal laboratory finding, for', 'example), symptom, or disease temporally associated with the use of a medicinal product,', 'whether or not considered related to the medicinal product.', 'In this study, adverse events will be captured from the time a patient signs the ICF to the', 'Follow-up Visit and include the following:', 'Any new sign, symptom, or disease;', 'Any new clinically significant or symptomatic laboratory/diagnostic test', 'abnormality;', 'Any clinically significant worsening of laboratory/diagnostic test abnormality;', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}